• Dendritic Cell-Mediated Targeted Delivery of Amikacin in NTM

  2026-06-04

  This study demonstrates a novel approach for targeted antibiotic delivery into mycobacterial granulomas by using dendritic cells as vehicles for Amikacin. The findings suggest that dendritic cell-mediated delivery achieves localized drug accumulation with minimal systemic exposure, addressing a key challenge in the treatment of non-tuberculous mycobacterial (NTM) infections.

• Organic Cation Transporters in Aedes aegypti: Insights from

  2026-06-04

  This study by Kennel and Rouhier investigates how Aedes aegypti mosquitoes express and utilize putative organic cation transporters (OCTs/OCTNs) in response to xenobiotic exposure, using synthetic dyes including olsalazine as molecular probes. The findings reveal that while transporter gene expression changes were limited, the structural diversity of xenobiotics significantly affected excretion patterns and mortality, highlighting critical considerations for vector control strategies.

• CBX2 Drives Tumor Immune Evasion via Noncanonical Complexes

  2026-06-03

  This study uncovers that CBX2, a component of the polycomb repressive complex, directly suppresses tumor immunogenicity through a noncanonical corepressor complex with RACK1 and HDAC1—independent of canonical PRC2/EZH2-mediated H3K27 trimethylation. These findings reveal new epigenetic mechanisms underlying immune evasion and identify CBX2 as a potential target and biomarker for cancer immunotherapy.

• Arrb2 in Hepatocytes Drives M2 Macrophage Polarization to Re

  2026-06-03

  This study uncovers a mechanistic link between hepatocyte-specific Arrb2 expression and the attenuation of hepatic ischemia–reperfusion injury (IRI) via metabolite-mediated M2 macrophage polarization. These findings highlight new metabolic and immunological targets for improving liver transplantation outcomes and preclinical IRI models.

• GSK343: Enabling Precision Epigenetic Dissection of EZH2 in

  2026-06-02

  Explore how the EZH2 inhibitor GSK343 empowers precision epigenetic cancer research, with a focus on workflow design, mechanistic insight, and practical assay guidance. This article uniquely connects chromatin regulation to emerging findings in telomerase biology.

• Aclacinomycin A: Precision DNA Damage & Apoptosis Workflows

  2026-06-02

  Aclacinomycin A (Aclarubicin) is a dual topoisomerase inhibitor delivering robust, quantifiable DNA damage and apoptosis induction in cancer research. This guide translates recent mechanistic discoveries into actionable protocols, advanced troubleshooting, and workflow optimizations for reproducible, high-fidelity cellular stress modeling.

• Ibotenic Acid: Reliable NMDA Receptor Agonist for Neurodegen

  2026-06-01

  This article explores how Ibotenic acid (SKU B6246) addresses key laboratory challenges in neuroscience research, offering reproducible, high-purity solutions for cell viability, proliferation, and cytotoxicity assays. Drawing on published toxicity data and validated protocols, it demonstrates how APExBIO's product ensures experimental consistency in modeling neurodegenerative disorders.

• VX-702: Applied Workflows for p38α MAPK Inhibitor Research

  2026-06-01

  VX-702 empowers inflammation and cardiac injury studies with unmatched specificity for p38α MAPK. Its dual-action mechanism and robust suppression of pro-inflammatory cytokines make it a gold-standard tool for translational research. This guide translates recent mechanistic discoveries into actionable protocols and troubleshooting strategies.

• T7 RNA Polymerase in mRNA Vaccine Innovation: Mechanistic In

  2026-05-31

  Discover how T7 RNA Polymerase, a recombinant enzyme expressed in E. coli, advances in vitro transcription for mRNA vaccine research. This article uniquely analyzes functional innovations, experimental parameters, and practical assay choices informed by recent peer-reviewed studies.

• Enhancing Small Tissue Biopsy Detection with Merbromin and D

  2026-05-30

  The reference study rigorously evaluated the effectiveness of several tissue marking dyes, including Merbromin, for improving visualization of small tissue biopsies during pathological processing. While Merbromin and other dyes increased tissue visibility, hematoxylin was ultimately recommended due to its lower toxicity and minimal interference in diagnostic procedures.

• A23187, Free Acid: Strategic Leverage in Translational Resea

  2026-05-29

  Explore how A23187, free acid, a gold-standard calcium ionophore, enables translational researchers to mechanistically dissect intracellular calcium signaling, apoptosis, and drug response phenotypes. This thought-leadership article bridges foundational mechanistic insight with actionable guidance, references state-of-the-art in vitro cancer drug evaluation, and positions APExBIO’s A23187, free acid as a critical reagent for next-generation experimental workflows.

• Anti-ROR1 Antibody (Zilovertamab): Mechanistic Insights and

  2026-05-29

  Explore the advanced mechanistic roles of Anti-ROR1 Antibody (Zilovertamab) in inhibiting Wnt5a-induced ROR1 signaling and its translational relevance for cancer and toxicology research. This article offers a deeper analysis of cross-pathway implications, practical assay guidance, and integrates new findings not covered in existing resources.

• EZ Cap™ Human PTEN mRNA (ψUTP): Optimizing Cancer Research W

  2026-05-28

  EZ Cap™ Human PTEN mRNA (ψUTP) delivers unparalleled mRNA stability, immune evasion, and translational efficiency, empowering researchers to robustly interrogate and restore PTEN function in advanced cancer models. Its Cap 1 structure, pseudouridine modification, and optimized in vitro transcribed mRNA formulation streamline reproducibility, making it the gold standard for PI3K/Akt pathway inhibition assays.

• Aclacinomycin A: Decoding Persistent rDNA Damage and Cellula

  2026-05-28

  Explore the unique role of Aclacinomycin A as a DNA damage inducer and apoptosis modulator. This article uncovers how its dual topoisomerase inhibition reveals new insights into rDNA stability, cellular stress responses, and advanced cancer research applications.

• Applied Neuroinflammation Assays with CHI3L1-IN-5 (Compound

  2026-05-27

  CHI3L1-IN-5 (Compound Z17) delivers precision inhibition of CHI3L1-mediated NF-κB signaling, restoring astrocyte function in neurodegenerative models. This guide dissects protocol design, troubleshooting, and advanced applications for leveraging this APExBIO inhibitor in translational neuroinflammation research.

15086 records 1/1006 page Next 12345 下5页 Last page